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Abstract 
With the advent of antimicrobial resistance, there is an urgent need for new strategies to treat 
infectious diseases. Antimicrobial peptides are considered as promising candidates, and therefore 
there is a need to understand their mechanism of action in order to exploit their therapeutic 
potential. To this end, fluorescent analogs are powerful tools to analyze their behavior and 
subcellular localization in cells and in vivo. However, the conjugation of fluorophores to 
antimicrobial peptides, especially in short sequences, can impair their biological activity, making 
the selection of the fluorescent label an essential step in these studies. In the present work, we have 
systematically modified a model antifungal hexapeptide with a collection of fluorophores covering 
broad physicochemical and spectral properties. The resulting conjugates have been examined in 
two different fungal species, in terms of their activity and intracellular localization. The biological 
results confirm the influence of the different fluorescent moieties on the subcellular localization 
of antimicrobial sequences, and provides an insight on the optimal fluorophores to be used in the 
preparation of fluorescent peptides for different bioimaging assays. 
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Introduction 
In the past decades, fluorescent dyes have been broadly used as tags to visualize and study the 
roles of peptides in cells and in vivo.1 For these studies, live cell imaging has become the 
technology of choice as it provides a direct readout of the localization of the peptides with high 
spatial and temporal resolution. In the context of antimicrobial peptides, several reports have 
described fluorescence labeling as an approach to study their mechanism of action2-4 as well as to 
develop imaging probes for the rapid identification of microbes at infection sites.5 In all cases, it 
is often assumed that fluorescently labeled peptides faithfully mimic the spatio-temporal dynamics 
of the native peptides, and fluorescent labels are typically chosen on the basis of 
excitation/emission wavelength, quantum yield, photobleaching, environmental sensitivity or 
chemical conjugation. Little attention has been paid to whether the fluorescent label might alter 
the physicochemical properties of the conjugate, and it is often unclear whether the fluorescent tag 
influences the uptake and localization of antimicrobial peptides inside living cells. In order to 
evaluate the impact that different fluorophores have in the biological properties of antimicrobial 
peptides and their application as imaging probes, we have synthesized a library of fluorescent 
conjugates based on the Peptide Antifungal 26 (PAF26).6 This rationally designed hexapeptide 
exhibits high potency against filamentous fungi (including human and crop pathogens), low 
toxicity against bacterial cells and negligible toxicity against mammalian cells. PAF26 is currently 
being used a model peptide for the characterization of the mode-of-action of small, cationic, cell 
penetrating antifungal peptides and for the design and development of synthetic antifungal 
peptides with improved properties for therapeutic uses.7 
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In the present work, we have conjugated 12 different fluorophores (either in-house or 
commercially available) to the peptide sequence of PAF26 and compared their biological activity, 
cellular uptake and intracellular localization using confocal live cell imaging. From these studies, 
we have observed that the activity of the conjugates is practically unaffected by the fluorescent 
labels whereas they accumulate in different intracellular regions depending on the fluorophore 
attached to the sequence. This systematic study will aid chemists working on peptide-based 
imaging agents in the selection of the fluorophores for different fluorescence-based biological 
applications. 
Results and Discussion 
Design and synthesis of a library of fluorescent antifungal peptides 
For many years, the synthesis of antimicrobial peptides has been adapted to combinatorial 
chemistry. However, libraries of antimicrobial peptides have been mainly focused on the 
optimization of the peptide sequences, either to enhance their antimicrobial activity, improve their 
selectivity against specific strains or pathogens, or to reduce their cytotoxicity in mammalian 
cells.8-10 Some antimicrobial peptides have been labeled with fluorophores in order to visualize 
their localization in cells by confocal microscopy.4,11 More recently, the high selectivity of 
antimicrobial sequences has been exploited to develop imaging contrast agents for the rapid 
identification of infection sites.12,13 In most reports, only one fluorophore is employed on the basis 
of its compatibility with the experimental procedures. However, conventional fluorophores differ 
largely in their physicochemical features,14,15 and therefore it is reasonable to expect that different 
fluorophores could induce variability in the activity and cellular localization properties of peptide 
sequences. For instance, Baker et al. reported the influence of different fluorescent labels in a 
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combinatorial library of A1R adenosine inhibitors, where significant differences were observed in 
the binding properties of several fluorescently-labeled inhibitors.16 In the context of short 
antimicrobial peptides, there are no reports of any systematic evaluation of their biological 
properties after conjugation to various fluorescent labels. Herein, we have designed a library based 
on the antimicrobial peptide sequence PAF26, which was modified with a total of 12 fluorophores 
covering the whole spectral range (from blue to near-infrared emission) and diverse 
physicochemical properties (Chart 1). In addition to conventional fluorophores (e.g. 
carboxyfluorescein, carboxyrhodamine, BODIPY, cyanine), we also included small fluorophores 
(e.g. NBD, dansyl), compounds with environmentally-sensitive properties (e.g. Nile Blue, 
malachite green, styryl), pH-sensitivity (e.g. naphthalimide) and esterase-activatable fluorophores 
(e.g. fluorescein diacetate). Overall, these fluorophores constitute a representative collection of the 
fluorescent labels that most chemists would employ for labeling any defined peptide sequence. 
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Chart 1. Fluorescent labels for the derivatization of the antimicrobial peptide PAF26. We 
employed 12 different fluorophores with suitable reactive groups (in red) for peptide labeling (e.g. 
carboxylic acids, sulfonyl chlorides, anhydrides, alkynes). Fluorophores 1, 2, 3 and 7 are 
commercially available, whereas the synthesis and characterization of all other fluorophores is 
described in the Experimental Procedures and the Electronic Supplementary Information (ESI).  
PAF26 (H-RKKWFW-NH2) is a short antimicrobial peptide which, like many other antimicrobial 
peptides, contains both cationic and hydrophobic residues,6,7 and therefore it is an excellent model 
for examining the influence of fluorophores in the properties of antimicrobial peptides. We 
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designed the synthesis of the hexapeptide using conventional solid-phase protocols in Rink amide 
polystyrene resin (Scheme 1). In order to incorporate suitable conjugation groups within the 
sequence of PAF26, we first synthesized two derivatives containing aminohexanoic or 
azidohexanoic spacers directly attached to the N-terminal group of PAF26. Through these spacers, 
fluorophores could be readily conjugated using their reactive groups (i.e., carboxylic acids, 
chlorides, anhydrides, sulfonyl chlorides or alkynes) without affecting the main recognition 
features of the antimicrobial peptide. Most library members were fully synthesized on solid 
support, including the coupling of the fluorophore, to render the final fluorescent PAF26 analogues 
upon acidic cleavage from the resin using reported procedures.17 Due to the lability of the 
fluorophores 11 and 12 (i.e., BODIPY and fluorescein diacetate, respectively) to acidic media, the 
corresponding derivatives PAF26-11 and PAF26-12 were prepared by 1,3-Huisgen dipolar 
cycloaddition using the azido-modified PAF26 and the fluorescent alkynes in solution phase 
(Scheme 1). All 12 fluorescent derivatives of PAF26 were purified by semi-preparative HPLC to 




Scheme 1. Solid-phase synthesis of a library of fluorescent antimicrobial peptides based on 
the hexapeptide PAF26. The peptide sequence of PAF26 was modified with amino- or 
azidohexanoic spacers at the N-terminus to enable the conjugation of different fluorophores, either 
by formation of amide bonds in solid-phase or by ‘click’ chemistry in solution. All 12 conjugates 
PAF26-1 to PAF26-12 were isolated in good yields and high purities. For the chemical structures 
of the fluorophores 1-12, see Chart 1. 
In vitro biological activity of fluorescent antifungal peptides 
After completing the synthesis of the library of fluorescent antimicrobial conjugates (PAF26-1 to 
PAF26-12), we measured their spectral properties and determined their IC50 values in two different 
fungal species (i.e., Neurospora crassa and Aspergillus fumigatus) as a measure of their cellular 
activity (Table 1). N. crassa has been widely used as an experimental model organism for 
filamentous fungi.18 A. fumigatus is a very important opportunistic pathogen responsible for 
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multiple human diseases, the most lethal of which, invasive pulmonary aspergillosis, causes 
around 200,000 deaths per year.19  
Conjugates incorporating small fluorophores (e.g., NBD (PAF26-3), naphthalimide (PAF26-4), 
dansyl (PAF26-7)) showed very similar antifungal activity when compared to the unlabeled 
sequence PAF26 in both fungal species. This observation is in line with previous reports where 
NBD or dansyl have been described as highly tolerated fluorescence labels for the derivatization 
of biomolecules.20 Larger fluorophores, including positively-charged fluorophores [i.e. rhodamine 
(PAF26-1), Nile Blue (PAF26-6), styryl dyes (PAF26-8 and PAF26-9)] and fluorescein-based 
structures (PAF26-2 and PAF26-12) induced only minor differences in the antifungal activity of 
PAF26, with all IC50 values in the low micromolar range. Two conjugates (PAF26-10 and PAF26-
11) showed slightly higher activity, being the two corresponding fluorophores [i.e. cyanine (10) 
and BODIPY (11)] permeable structures that have been reported for the preparation of a range of 
fluorescent probes.21-25 Altogether, these results corroborate the minor influence of the 
fluorescence labels on the antifungal activity of fluorescent PAF26 conjugates, with the smallest 
impairment being observed for conjugates including small fluorophores. 
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Table 1. Spectral properties and antifungal activities of the fluorescent antimicrobial sequences. 
Compound exc. (nm) em. (nm) MW IC50 (N. crassaǂ) IC50 (A. fumigatusǂ) 
PAF26 n.d. n.d. 949.6 4.0 ± 0.7 8.0 ± 0.3 
PAF26-1¥ 563 593 1530.8 3.8 ± 0.1 6.9 ± 0.2 
PAF26-2¥ 498 529 1419.7 5.3 ± 0.2 9.1 ± 0.3 
PAF26-3 488 552 1225.6 4.4 ± 0.3 7.9 ± 0.1 
PAF26-4 450 532 1285.7 4.2 ± 0.2 8.0 ± 0.2 
PAF26-5 635 n.d. 1416.8 4.1 ± 0.4 9.7 ± 0.5 
PAF26-6 635 679 1476.8 3.2 ± 0.2 5.8 ± 0.2 
PAF26-7 300 350 1295.7 4.0 ± 0.1 7.9 ± 0.2 
PAF26-8 465 706 1408.8 3.0 ± 0.1 7.7 ± 0.1 
PAF26-9 487 621 1466.9 2.6 ± 0.2 7.2 ± 0.4 
PAF26-10 633 660 1547.9 2.0 ± 0.1 4.2 ± 0.4 
PAF26-11 505 540 1494.8 2.2 ± 0.2 3.7 ± 0.2 
PAF26-12¥ 503 530 1585.7 5.3 ± 0.2 9.9 ± 0.4 
ǂ IC50 values (µM) represented as means ± standard deviations (n=3). 
¥ Values obtained for the mixture of 5 and 6-carboxyisomers. 
Fluorescence confocal live cell imaging studies to analyze the localization of PAF26 
conjugates in fungal cells 
Next we performed live cell imaging experiments to examine the cellular uptake and intracellular 
localization of the different conjugates in N. crassa and A. fumigatus by confocal laser scanning 
microscopy. Concentrations in the low micromolar range were used, as these have been previously 
optimized for the non-passive uptake of PAF26.16 As shown in Fig 1, the rhodamine PAF26-1 
derivative localized to the cell envelope (comprising the plasma membrane and the cell wall) and 
the intracellular vacuolar/vesicular system of N. crassa conidial germlings, The positive charge of 
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the rhodamine fluorophore might favour the interaction with the negatively charged phospholipids 
in the plasma membrane. In contrast, the carboxyfluorescein derivative PAF26-2 showed a similar 
pattern of intracellular vacuolar distribution but reduced staining on the cell envelope (Fig. 1). The 
negative charge of carboxyfluorescein reduced the affinity of the conjugate for the cell envelope, 
with slower internalization (Table 1). Similarly, the diacetylated derivative (PAF26-12) showed 
preferential staining of the vacuolar lumens with no fluorescence detected in the plasma or 
intracellular membranes, because its fluorescence emission is triggered upon reaction with 
intracellular esterases (Fig. S1 in ESI). We performed co-localization experiments between 
PAF26-12 and PAF26-1 and observed that both conjugates displayed a similar pattern of cellular 
uptake, first appearing in small vesicles and then accumulating in larger cell vacuoles (Fig. S2 in 
ESI).  
 
Figure 1. Confocal fluorescence microscope images of conidial germlings of N. crassa after 
incubation with PAF26-1, PAF26-2 or PAF26-8. A) Fluorescence images of N. crassa after co-
staining with the rhodamine PAF26-1 derivative (red, 0.5 μM) and the carboxyfluorescein 
derivative PAF26-2 (green, 0.5 μM) at 25 oC. Scale bar: 2 μm; v: vacuole. B) Imaging of N. crassa 
after co-staining with the styryl PAF26-8 derivative (red, 1 μM) and the rhodamine PAF26-1 
derivative (yellow, 1 μM) at 25 o C. Scale bar: 5 μm; v: vacuole. 
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Conjugates including small fluorophores, such as NBD (PAF26-3) or naphthalimide (PAF26-4), 
displayed similar intracellular vacuolar/vesicular localization, both in conidial germlings of N. 
crassa and A. fumigatus (Fig. S3 in ESI). Notably, the pH-sensitive properties of PAF26-4 enabled 
preferential imaging of acidified vacuoles as opposed to the general vacuolar and vesicular 
structures staining observed with PAF26-1 (Fig. S4 in ESI), demonstrating the possibility of 
monitoring intracellular pH changes in these subcellular structures. Conjugates including 
environmentally-sensitive fluorophores such as malachite green, Nile Blue or dansyl (PAF26-5, 
PAF26-6 and PAF26-7) showed marginal staining in fungal cells, suggesting the potential 
accumulation of these peptide conjugates in neutral hydrophilic microenvironments (e.g. 
vacuoles), in which these fluorophores exhibit very low quantum yields.26,27  
On the other hand, cationic styryl-based fluorophores (PAF26-8 and PAF26-9) showed 
remarkably enhanced staining of the envelope of fungal cells. PAF26-8 brightly stained the plasma 
and intracellular vacuolar/vesicular membranes of N. crassa to a similar extent than PAF26-1 (Fig. 
1), but without marked accumulation in the vacuole lumens. Imaging experiments using the 
PAF26-9 derivative also showed a similar behavior in both N. crassa and A. fumigatus (Fig. S5 in 
ESI). As observed for PAF26-1, the cationic character of the styryl fluorophores favoured the 
rapid interaction with anionic components of the cellular membranes and enhanced their 
internalization (Table 1). Interestingly, and in contrast to the results obtained with N. crassa (Fig. 
1), when we incubated PAF26-8 with A. fumigatus, we did not observe the uptake of the 
fluorescent conjugate into healthy cells and hyphae were only stained once the cell membrane 
structure was compromised (Fig. S6 and Movie S1 in ESI). These results highlight differences in 
the internalization of PAF26-8 by cells of different fungal species, suggesting the possibility of 
using fluorescent labels as means to improve the selectivity of antimicrobial sequences. 
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Finally, both cyanine and BODIPY-based conjugates (PAF26-10 and PAF26-11, respectively) 
displayed a markedly different staining pattern when compared to all other members of the PAF26 
library. The cyanine derivative (PAF26-10) brightly stained fungal cells and, besides localizing 
within vacuoles and vesicle lumens, it also stained other cytoplasmic organelles. Dual labeling 
experiments with the carboxyfluorescein derivative PAF26-2 confirmed the presence of PAF26-
10 in the same vacuolar and vesicular organelles but also indicated its localization in different 
cytoplasmic organelles (Fig. 2). The BODIPY derivative PAF26-11 exhibited general staining of 
the cytoplasm with no specific accumulation in subcellular organelles, as shown by co-localization 
experiments with PAF26-1 (Fig. 2). 
Furthermore, we compared the staining of N. crassa cells using the fluorescent peptides PAF26-
1, PAF26-2, PAF26-10 and PAF26-11 and their corresponding fluorophores alone (Fig S7 in 
ESI). In these experiments, we observed that the PAF26 sequence is essential for the interaction, 
internalization and accumulation of the fluorescent conjugates in the vacuoles of fungal cells, as 
the fluorophores alone were not able to enter the cells or stained non-specifically intracellular 
environments (e.g. the BODIPY fluorophore showed bright, general staining of lipid-rich 
subcellular structures).      
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Figure 2. Fluorescence microscope images of conidial germlings of A. fumigatus after 
incubation with PAF26-10 or PAF26-11. A) Fluorescence images of A. fumigatus after co-
staining with the cyanine PAF26-10 (red, 1 μM) and the carboxyfluorescein PAF26-2 (green, 1 
μM) derivatives at 37 oC. Scale bar: 1 μm. B) Fluorescence images of germinated A. fumigatus 
after co-staining with the BODIPY PAF26-11 (green, 2 μM) and the rhodamine PAF26-1 (red, 2 
μM) derivatives at 37 o C. Scale bar: 1 μm. 
Finally, in view of the bright fluorescence signals in fungal cells upon incubation with PAF26-10 
(Figure 2A) and its emission in the near-infrared region (em.: 660 nm, Table 1), we assessed the 
suitability of PAF26-10 for whole-body in vivo fluorescence imaging experiments in mice with 
fungal lung infection. Near-infrared fluorophores are advantageous for in vivo imaging as the low 
autofluorescence background in such region of the spectra enhances the signal-to-noise ratios.28-30 
We determined the background and fluorescence signals in mice that had been treated with 
PAF26-10, and observed that the cyanine fluorophore was bright enough to provide a detectable 
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signal from live animals using whole-body fluorescence imaging (Fig. S8 in ESI). These results 
are in good agreement with previous reports of cyanine-labeled peptides for in vivo imaging of 
cancer cells in xenograft models.31,32  
Altogether, the systematic evaluation of a library of fluorescent PAF26-based antimicrobial 
peptides provided important clues of the optimal fluorophores for the preparation of fluorescent 
peptides and their application in bioimaging experiments. Whereas positively-charged structures 
(e.g. rhodamine, styryl) favor the interaction with the anionic membrane components, neutral (e.g. 
NBD) and negatively-charged fluorophores (e.g. fluorescein) preferentially accumulate in 
vacuoles, and pH-sensitive fluorophores (e.g. naphthalimide) offer the possibility of visualizing 
specific intracellular processes in real time, such as vacuolar acidification. Cell permeable 
fluorophores (e.g. cyanine) provide bright cytosolic staining and show good discrimination from 
background signals in whole-body in vivo fluorescence imaging. These results suggest that, 
whereas the PAF26 sequence is the main component responsible for the antifungal activity of the 
fluorescent peptides, the incorporation of different fluorescent moieties into antimicrobial 
sequences can lead to major redistributions of the peptide sequences to different subcellular 
environments. 
Conclusions 
Fluorescently labeled peptides are powerful tools for image-based mechanistic studies in cells. 
However, little is known about the influence of fluorescent tags in the uptake and localization of 
peptides inside the cells, and fluorophores are primarily selected on the basis of their spectral 
properties. We have evaluated the impact of different fluorophores (either commercially available 
or synthetically accessible) in the biological properties of a small model antimicrobial peptide by 
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synthesizing a library of fluorescent derivatives of the antifungal hexapeptide PAF26. Solid-phase 
peptide synthesis followed by conventional amide formation or solution-phase ‘click’ conjugation 
for acid-sensitive fluorophores rendered a collection of 12 fluorescent conjugates with broad 
spectral and physicochemical properties. The assessment of the fluorescent peptides in two fungal 
species (N. crassa and A. fumigatus) indicated the minimal impact of the fluorescent labels on the 
antimicrobial activity of the PAF26 sequence (with all conjugates displaying IC50 values in the 
low micromolar range) whereas major changes in the localization pattern were observed upon 
conjugation to different fluorophores. This systematic study will aid chemists working on peptide-





8-(Dimethylamino)-3-oxatricyclo[trideca-1,5,7,9,11-pentaene]-2,4-dione (4). 2.0 mL of 
dimethylamine aqueous solution (19.9 mmol) and a catalytic amount of CuSO4 were added to a 
suspension of 4-bromo-1,8-naphthalenedicarboxylic anhydride (1.9 mmol) in DMF (50 mL). The 
mixture was then refluxed for 1.5 h, after which the solvent was evaporated under vacuum. 
Compound 4 was crystallized from ethanol as a yellow solid (275 mg, 57% yield). HPLC: tR: = 
4.74 min; MS (m/z): [M+H]+ calcd for C14H11NO3: 242.1; found: 242.2; 1H NMR (500 MHz, 
DMSO-d6): δ 8.59 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 7.2 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 7.76 (t, 
J = 7.9 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 2.51 (s, 6H); 13C NMR (126 MHz, DMSO-d6): δ 162.0, 
160.8, 157.8, 134.8, 133.6, 133.0, 125.5, 124.1, 119.3, 113.2, 108.4, 44.7. 
N-(4-((4-carboxyphenyl)(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-
ylidene)-N-methylmethanaminium (5). 4-(Bis(4-(dimethylamino)phenyl)methyl)benzoic acid 
(0.70 mmol) and p-chloranil (1.05 mmol) were dissolved in 30 mL CHCl3, and 0.5 mL AcOH was 
added to the solution. The solution was stirred for 1.5 h at 35oC. Compound 5 was crystallized in 
water to yield a green solid (176 mg, 70% yield). HPLC: tR: = 4.28 min; MS (m/z): [M+] calcd for 
C24H25N2O2+: 373.2; found: 373.2; 1H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.14 (d, J = 
8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 9.4 Hz, 2H), 7.11 (d, J = 9.5 Hz, 2H), 6.98 (d, J 
= 9.0 Hz, 2H), 6.64 (d, J = 9.0 Hz, 2H), 3.31 (s, 6H), 3.06 (s, 6H); 13C NMR (126 MHz, DMSO-
d6) δ 166.7, 157.0, 152.9, 151.6, 145.5, 144.6 (x 2), 140.5 (x 2), 132.7, 129.7, 128.9, 126.9 (x 2), 
121.2 (x 2), 114.7 (x 2), 111.9 (x 2), 41.1 (x 2), 40.6 (x 2). 
N-(5-(5-carboxybutanamido)-9H-benzo[a]phenoxazin-9-ylidene)-N-ethylethanaminium (6). 
Nile Blue chloride (0.33 mmol) was dissolved in DCM together with glutaric anhydride (1 mmol) 
and DIPEA (1.14 mmol). The mixture was stirred at r.t. overnight. The crude mixture was then 
diluted with DCM and washed twice with water and then evaporated under vacuum. The crude 
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was then purified by column chromatography (DCM: MeOH, 9:1) to yield compound 6 as a dark 
blue solid (142 mg, 81% yield). HPLC: tR: = 4.05 min; MS (m/z): [M+] calculated for C25H26N3O4+: 
432.2; found: 432.2; 1H NMR (500 MHz, DMSO-d6) δ 8.75 (d, J = 8.0 Hz), 8.23 (s), 2.86 (q, J = 
7.2 Hz), 2.35 (dt, J = 14.8 Hz, 4.6 Hz), 2.24 (t, J = 7.4 Hz), 1.93 – 1.77 (m), 1.71 (dd, J = 14.8 Hz, 
7.4 Hz), 1.15 (d, J = 6.6 Hz); 13C NMR (126 MHz, DMSO-d6) δ 178.4, 174.6, 174.6, 164.2, 51.5, 
33.3, 21.6, 21.3, 21.3, 20.5, 20.5, 19.1, 19.1, 18.9, 14.5, 14.5, 14.5, 12.3, 12.0. 
1-(5-carboxypentyl)-4-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dienyl)pyridin-1-ium 
bromide (8). 4-Methylpyridine (5.4 mmol) and ethyl 6-bromohexanoate (6.5 mmol) were 
dissolved in 20 mL of ACN, the mixture was refluxed at 90oC overnight. 1-(6-ethoxy-6-oxohexyl)-
4-methylpyridinium was precipitated in cold Et2O:hexane (1:1) to yield a light brown solid (1.9 g, 
quantitative yield). HPLC: tR: = 3.58 min; MS (m/z): [M+] calcd for C14H22NO2+: 236.2; found: 
236.2. 1-(6-ethoxy-6-oxohexyl)-4-methylpyridinium (1.6 mmol) and 3-(4-
(dimethylamino)phenyl)acrylaldehyde (2 mmol) were dissolved in 10 mL of EtOH in a microwave 
reaction vessel, then pyrrolidine (1.6 mmol) was added to the solution. The mixture was irradiated 
under microwave for 10 min at 120 oC, and the crude was purified by column chromatography 
(DCM: MeOH, 9:1) to yield 4-((1E,3E)-4-(4-(dimethylamino)phenyl)buta-1,3-dien-1-yl)-1-(6-
ethoxy- 6-oxohexyl)pyridin-1-ium bromide as a red solid (853 mg, quantitative yield). The ethyl 
ester (0.25 mmol) was dissolved in 2 mL THF and 1 mL MeOH, mixed with LiOH (1.25 mmol) 
in water (1 mL) and stirred overnight at r.t. to yield the carboxylic acid which was used in situ 
without any further purification. Characterization data for the ester: HPLC: tR: = 4.73 min; MS 
(m/z): [M+] calcd for C25H33N2O2+: 393.3; found: 393.4; 1H NMR (500 MHz, DMSO-d6) δ 8.80 
(d, J = 6.9 Hz, 2H), 8.05 (d, J = 7.0 Hz, 2H), 7.87 – 7.77 (m, 2H), 7.48 (d, J = 8.9 Hz, 2H), 7.02 
(d, J = 6.6 Hz, 2H), 6.78 – 6.71 (m, 2H), 4.05 (q, J = 7.1 Hz, 2H), 2.99 (s, 6H), 2.31 (td, J = 7.3, 
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2.1 Hz, 2H), 1.95 – 1.83 (m, 2H), 1.61 – 1.52 (m, 2H), 1.38 – 1.25 (m, 2H), 1.19 (t, J = 7.1 Hz, 
2H),  1.17 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 173.2, 153.6, 151.6, 144.1, 142.7, 
129.6, 124.0, 123.6, 123.2, 112.5, 60.2, 59.5, 53.6, 33.6, 30.6, 25.3, 24.2, 23.0, 14.6. 
(E)-1-(5-carboxypentyl)-4-(4-(Dibutylamino)styryl)pyridin-1-ium bromide (9). (3E,5E)- 1-
(6-ethoxy-6-oxohexyl)-4-methylpyridinium (1.6 mmol) and 4-(dibutylamino)benzaldehyde (2 
mmol) were dissolved in 10 mL of EtOH in a microwave reaction vessel, then pyrrolidine (1.6 
mmol) was added to the solution. The mixture was left to react under microwave irradiation for 10 
min at 120oC. The crude was purified by column chromatography (DCM: MeOH, 9:1) to yield 
(E)-4-(4-(dibutylamino)styryl)-1-(6-ethoxy-6-oxohexyl)pyridin-1-ium bromide as a purple solid 
(703 mg, quantitative yield). The ethyl ester (0.25 mmol) was dissolved in 2 mL THF and 1 mL 
MeOH, mixed with LiOH (1.25 mmol) in water (1 mL) and stirred overnight at r.t. to yield the 
carboxylic acid which was used in situ without any further purification. Characterization data for 
the ester: HPLC: tR: = 5.76 min; MS (m/z): [M+] calcd for C29H43N2O2+: 451.3; found: 451.4. 1H 
NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 7.0 Hz, 2H), 8.05 (d, J = 7.1 Hz, 2H), 7.91 (d, J = 16.0 
Hz, 1H), 7.57 (d, J = 8.9 Hz, 2H), 7.12 (d, J = 16.0 Hz, 1H), 6.74 (d, J = 9.1 Hz, 2H), 4.41 (t, J = 
7.4 Hz, 2H), 4.05 (q, J = 7.1 Hz, 4H), 3.41 – 3.34 (m, 3H), 2.31 (td, J = 7.3, 1.6 Hz, 2H), 1.98 – 
1.84 (m, 2H), 1.63 – 1.47 (m, 4H), 1.41 – 1.25 (m, 4H), 1.20 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 7.1 
Hz, 3H), 0.93 (t, J = 7.4 Hz, 6H).13C NMR (126 MHz, DMSO) δ 173.2, 154.3, 150.4, 143.9, 142.8, 
139.1, 131.0, 122.7, 122.2, 117.0, 112.0, 60.2, 59.3, 53.6, 50.3, 33.6, 30.6, 29.5, 25.3, 23.1, 20.1, 
14.6. 
2-((1E,3Z)-3-(5-carboxypyridin-2-yl)-5-((E)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-
dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide (10). 3H-Indolium-2,3,3-tetramethyl iodide 
(0.72 mmol), NaOAc (0.72 mmol) and 6-(1,3-dioxopropan-2-yl) nicotinic acid (0.36 mmol) were 
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added to a microwave reaction vessel with 10 mL Ac2O:AcOH (1:1). The mixture was then heated 
up to 160oC under microwave irradiation for 0.5 h, after which the solvent was evaporated under 
vacuum. The crude was then purified using column chromatography (DCM:MeOH, 98:2 to 9:1) 
to yield compound 10 as a blue solid (144 mg, 80% yield). HPLC: tR: = 4.72 min; MS (m/z): [M+] 
calcd for C33H34N3O2+: 504.3; found: 504.4; 1H NMR (500 MHz, DMSO-d6) δ 9.26 (d, J = 1.3 Hz, 
1H), 8.44 (s, 1H), 8.41 (s, 1H), 8.40 (d, J = 2.2 Hz, 1H), 8.39 (d, J = 2.2 Hz, 1H), 7.65 (d, J = 7.4 
Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.42 (dd, J = 8.0, 1.2 Hz, 2H), 7.40 (d, J = 1.1 Hz, 3H), 7.28 
(ddd, J = 7.4, 6.5, 1.9 Hz, 2H), 5.85 (d, J = 14.3 Hz, 1H), 3.39 (s, 6H), 1.76 (s, 12H). 13C NMR 
(126 MHz, DMSO) δ 177.5, 152.8, 152.4, 141.4, 139.9, 135.3, 133.7, 131.7, 131.1, 129.3, 128.8, 
126.9, 126.3, 123.4, 11.9, 101.4, 52.6, 32.1, 27.5. 
4-(1,3,5,5,7,9-Hexamethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl)-N-
(prop-2-yn-1-yl)benzamide (11). 2,4-Dimethylpyrrole (4.5 mmol) and 4-carboxybenzaldehyde 
(2 mmol) were dissolved in DCM under Ar. One drop of TFA was added and the solution was 
stirred at r.t. until complete consumption of the aldehyde. Then, a solution of 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (2 mmol) in DCM was added, and the stirring continued for 10 min 
followed by addition of triethylamine (4 mL) and BF3Et2O (4 mL). After stirring for another 2 h 
the reaction mixture was washed with water and dried, then solvent was evaporated under vacuum. 
The carboxylic acid was then purified by column chromatography (DCM: MeOH, 95:5). The crude 
product was then concentrated and precipitated (AcOEt: hexane, 1:1) to yield a dark red oil (160 
mg, 20 % yield). HPLC: tR: = 5.81 min; MS (m/z): [M+] calcd for C20H19BF2N2O2: 368.2; found: 
368.2. Then, the carboxylic acid (0.19 mmol) was dissolved with oxyma (0.57 mmol) in DCM and 
stirred for 5 min. DIC (1.14 mmol) was added and stirred for another 2 min. Propargylamine (0.21 
mmol) was then added and whole mixture was stirred at r.t. for 3 h. Compound 11 was isolated as 
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a bright orange solid (17 mg, 22% yield over all steps). HPLC: tR: = 5.80 min; MS (m/z): [M+H]+ 
calcd for C23H22BF2N3O: 406.2; found: 406.2; 1H NMR (500 MHz, DMSO-d6) δ 8.05 (d, J = 8.4 
Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 6.20 (s, 2H), 5.76 (s, 1H), 4.09 (dd, J = 5.6, 2.5 Hz, 2H), 2.47 
(s, 6H), 1.35 (s, 6H); 13C NMR (126 MHz, DMSO) δ 165.7, 143.2, 135.8, 134.8, 130.9, 128.7, 
122.0, 112.1, 111.6, 98.8, 73.4, 29.1, 14.7, 14.6. 
3-Oxo-6-(prop-2-yn-1-ylcarbamoyl)-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl 
diacetate (12). 5,6-carboxyfluorescein diacetate (0.43 mmol) and oxyma (1.29 mmol) were 
dissolved in DCM and stirred for 5 min. Then DIC (2.58 mmol) was added to the mixture, stirred 
for 2 min and propargylamine (1.29 mmol) was added. The whole mixture was stirred at r.t. for 3 
h then evaporated under vacuum. Compound 12 was purified by column chromatography (DCM: 
MeOH: AcOH, 98:1:1) to yield a yellow oil (175 mg, 82% yield); HPLC: tR: = 5.36 min; MS 
(m/z): [M+H]+ calcd for C28H19NO8: 497.1; found: 497.8; 1H NMR (500 MHz, DMSO-d6) δ 9.31 
(t, J = 5.5 Hz, 1H), 9.13 (t, J = 5.5 Hz, 1H), 8.54 (dd, J = 1.6, 0.7 Hz, 1H), 8.29 (dd, J = 8.1, 1.6 
Hz, 1H), 8.22 (d, J = 1.4 Hz, 1H), 8.16 (dd, J = 8.1, 0.7 Hz, 1H), 7.83 (t, J = 1.0 Hz, 1H), 7.55 (dd, 
J = 8.0, 0.7 Hz, 1H), 7.37 – 7.28 (m, 2H), 7.02 – 6.90 (m, 6H), 4.12 (dd, J = 5.5, 2.5 Hz, 2H), 4.00 
(dd, J = 5.5, 2.5 Hz, 2H), 3.16 (t, J = 2.5 Hz, 1H), 3.08 (t, J = 2.5 Hz, 1H), 2.29 (s, 3H), 2.29 (s, 
3H).13C NMR (126 MHz, DMSO) δ 170.3, 169.0, 167.4, 155.5, 152.4, 150.8, 135.5, 134.9, 130.0, 
129.4, 119.1, 115.9, 110.6, 82.4, 81.4, 73.5, 29.6, 20.9. 
Solid-phase peptide synthesis. All peptides were manually synthesized in polystyrene syringes 
fitted with a polyethylene porous disc using Fmoc-based SPPS. Solvents and soluble reagents were 
removed by suction. The Fmoc group was removed with piperidine: DMF (1:4) (1 × 1 min, 2 × 10 
min). Peptide synthesis transformations and washings were performed at r.t. For peptide 
elongation, after the Fmoc group was removed, resins were washed with DMF (4 × 1 min), DCM 
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(3 × 1 min) and DMF (4 x 1 min). Unless otherwise noted, standard coupling procedures were 
used with DIC (3 eq.) and OxymaPure (3 eq.) in DMF for 1-2 h and 5-min of pre-activation. The 
completion of the coupling was monitored by the Kaiser test.33 Then, resins were filtered and 
washed with DCM (4 x 1 min) and DMF (4 x 1 min).  
Synthesis of the peptides PAF26-1/10. For conjugates PAF26-1, PAF26-2, PAF26-5, PAF26-
6, PAF26-8, PAF26-9, PAF26-10, standard amide bond formation coupling conditions with 
fluorophore-COOH (3 eq.), DIC (3 eq.) and OxymaPure (3 eq.) in DMF were used. For compounds 
PAF26-3, PAF26-4 and PAF26-7, coupling of the dyes was accomplished by incubation of the 
peptide with the fluorophore (3 eq.) and DIPEA (3 eq.) in DMF. All resins were then washed with 
DMF (4 × 1 min) and DCM (3 × 1 min). For the cleavages, resins were stirred in 5 mL of TFA: 
H2O (95:5) for 2 h at r.t. as previously reported.34 The beads were washed with TFA thoroughly 
and the peptides precipitated with ice-cold Et2O after rotary evaporation before final purification 
by semi-preparative HPLC. Characterization details can be found in the ESI.  
Synthesis of the peptides PAF26-11/12. Azido-derivatized peptides were cleaved from the resin 
by cleavage with 5 mL of TFA: H2O: TIS (95:2.5:2.5) for 2 h at r.t. The beads were washed with 
TFA thoroughly and the peptides precipitated with ice-cold Et2O after rotary evaporation. For the 
conjugation was performed, the peptide (1 eq.), ascorbic acid (1 eq.), tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl] amine (TBTA) (0.3 eq.) and CuSO4 (0.3 eq.) were dissolved in H2O, and the 
corresponding alkynes (2 eq.) were added using a minimum amount of MeOH, leaving the reaction 
for aprox. 4 h at r.t. The reaction was monitored with HPLC, and upon completion, peptides were 
purified by semi-preparative HPLC. Characterization details can be found in the ESI. 
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Measurement of spectral properties. Spectroscopic data were recorded on a Synergy HT 
spectrophotometer (Biotek). Compounds were dissolved at concentrations around 10 M-50 M 
in phosphate buffer saline (PBS) and spectra were recorded at r.t. 
Culturing of N. crassa and A. fumigatus. Cultures of N. crassa (wild type strain  2489 from the 
Fungal Genetics Stock Center) and A. fumigatus (CEA10 strain from the fungal stock collection 
of the Manchester Fungal Infection Group) were grown on solid 100% Vogel’s agar medium35 at 
25 °C for 3-5 days under constant light (N. crassa) or 37 oC for 4-5 days (A. fumigatus). The spores 
(conidia) were then harvested from the plates with sterile deionized water (N. crassa) or 0.05% 
Tween 80 in sterile deionized water (A. fumigatus), and the spore density was determined with a 
haemocytometer.  
Antifungal activity measurements. The BacTiter-GloTM Microbial Cell Viability Assay kit 
(Promega), with CELLSTAR white polystyrene flat bottomed 96-well plates (Greiner), were used 
for these assays. Each antifungal peptide, at an appropriate serial diluted concentrations, was 
mixed with conidia of N. crassa or A. fumigatus to reach a final volume of 100 μL per well and a 
final conidial concentration of 5 × 105 cells/mL in 10% liquid Vogel’s medium. After 24 h of 
incubation (at 25 oC for N. crassa or 37 oC for A. fumigatus), the amount of fungal growth was 
determined by measurement of the luminescence in a TriStar LB 941 multimode microplate reader. 
IC50 values were determined using four parameter logistic regression. Data analysis was performed 
using Sigma Plot 10.0. Values are represented as means ± s.e.m. from two independent 
experiments (n = 3). 
Confocal live cell microscopy. Conidia at a concentration of 5 × 105 cells/mL were dispensed into 
the wells of an 8-well slide culture chamber (ibidi USA Inc., Madison, WI) and incubated for 3 h 
at 25 oC (N. crassa) or for 16 h at 37 oC (A. fumigatus) in 10% Vogel’s medium in order to allow 
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germination to occur before the addition of antifungal peptide. The peptide was added to produce 
the appropriate final concentration immediately before the live-cell imaging was initiated.  
Individual germinated spores of each species were imaged for periods of up to 1 h at the same 
temperature as they had previously been incubated at in a temperature-controlled chamber 
mounted on the microscope stage. The live-cell imaging was performed with a Leica TCS SP8 
confocal laser scanning microscope equipped with photomultiplier tubes, hybrid GaAsP detectors 
and a 63× water immersion objective and. White light (450-750 nm), argon ion (458 nm, 476 nm, 
488 nm and 496 nm) and blue diode lasers (405 nm) were used for excitation. Images were 
processed and analyzed using Imaris 3D/4D image processing and analysis software v 8.0 
(Bitplane, Zurich, Switzerland). Details on the excitation and emission wavelengths used for all of 
the PAF26-1/12 conjugates are shown in Table S2 in the ESI.  
In vivo fluorescence imaging. Animal experiments were carried out in compliance with national 
and European regulations and were approved by the animal ethics committee of KU Leuven (p103-
2012).  9-week-old female Balb/C mice of (Balb/cAnNCrl from Charles River Laboratories, bred 
at the KU Leuven animal facility, Leuven, Belgium) were kept in individually ventilated cages 
with free access to food and water. Immune competent mice (n = 3) were infected by inhalation of 
a fungal yeast cell suspension (C. gattii R265, 50,000 CFUs in 20 µL PBS, 10 µL per nostril) under 
transient isoflurane gas anesthesia (2 % in pure O2). Three weeks after infection, whole-body 
fluorescence imaging was carried out under isoflurane anesthesia on an IVIS Spectrum system 
with Living Image software (version 4.5.2, Perkin Elmer). The fluorescence signal intensity was 
measured using the excitation/emission 640/680 filter pair before and 5 min after intratracheal 
administration of 7.5 nmol of the PAF26-10 derivative. 
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Supporting Information. NMR spectra and additional characterization data for the fluorescent 
PAF26 conjugates, additional imaging data. This material is available free of charge via the 
Internet at http://pubs.acs.org. 
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